Category Archives: Non classé

We are delighted to welcome Gilles Devouassoux to the laboratory, with the shared ambition of strengthening our integrated fundamental, translational and clinical research activities, with a particular focus on bronchial inflammatory pathologies linked to respiratory viral infections. Gilles will bring to VirPath all his scientific and clinical expertise in pulmonary pathophysiology and his know-how in the implementation and coordination of international clinical trials for the development of bi...

This collaborative public-private research and development program aims to contribute to the management and prevention of microbiological and virological contamination risks, for better protection and quality of indoor air in confined spaces. Alongside their partners VirexpR, Conidia-Coniphy and IMéBIO, Virnext and the VirPath laboratory are committed to develop an ambitious technology offering that is unique in Europe. The aim of the GESPPAIR consortium is also to bring together other indus...

An excellent meeting with Bruno Marchand, Mayor of Quebec City, Carl Viel, CEO of Quebec International, and Guy Boivin, Professor at the Laval University’s Faculty of Medicine on the occasion of the 35th Jacques Cartier Meeting Days.  Fruitful discussions on the scientific and technological cooperation between our territories, focused on the study and control of emerging and re-emerging respiratory viruses, a major current health and economic challenge. The France-Canada Interna...

AIS Biotech, spun off from our R&D partnership with the Center for Research on Plant Macromolecules CERMAV, is the winner in the Health theme of the 25th edition of the i-Lab competition, organized by the Ministry of Higher Education, Research and Innovation in partnership with bpifrance. AIS Biotech project is to develop a new class of anti-infective biomedicines based on complex biosynthetic glycopolymers, is one of the 79 projects selected from among the 400 applications, which will be su...

Dear partners and network,The quarterly newsletter of Virnext is now available. This is a great opportunity to stay tuned and learn about the main scientific achievements and track record of the Technological Research Platform Virnext and its spin-offs.This first newsletter is devoted to a retrospective of the main value creations of our teams in 2022.Link to the newsletter: https://lnkd.in/dwxC7DZfPlease feel free to share this announcement. Thank you for your support and trust....

Survir is a public-private research and development program labeled by the Lyonbiopôle health competitiveness cluster and supported by the Regional Innovation Fund of the Auvergne-Rhône-Alpes Region and Bpifrance. With our partners AXO Science and EPIMOD, we are engaged in the last phase of this R&D booster 2021 partnership program which aims to develop an automated platform for the rapid characterization and quantification by imaging of a large panel of pathogenic respiratory viruses....

In this study, we report the efficacy, safety, and immunogenicity of BIMERVAX® in cynomolgus macaque model of SARS-CoV-2 we developed with Cynbiose. Prime-boost vaccination induces high levels of RBD-specific IgG binding and neutralizing antibodies against several SARS-CoV-2 variants, as well as a balanced Th1/Th2 cellular immune response. Remarkably, BIMERVAX® vaccination prevents SARS-CoV-2 replication in the lower respiratory tract and significantly reduces viral load in the upper respirato...

This excellence preclinical research network is dedicated to microbiome and infectious diseases research field and offers synergic expertise and large customized services in high-throughput sequencing, biomanufacturing, imaging, microfluidics, specific analyses, biomarkers, preclinical and clinical activities. Virnext brings to the Cynbiome® network its expertise in emergent and re-emergent respiratory viruses and provides a large panel of in vitro and in vivo preclinical models of infection...

Our partner IMéBIO, a company expert in modular technical environments for biotechnology and health, has delivered a mobile and autonomous BSL-3 laboratory of 45 m2 to allow us to amplify our collaborative research activities in the fight against emerging and re-emerging infectious diseases. These additional laboratory spaces will in particular make it possible to accelerate our various R&D programs carried out with our spin-off VirexpR in the field of microbiological contamination of indoo...

Virnext is very proud to have contributed with its partner Cynbiose to preclinical assessment and accelerating transfer to clinical trial of the HIPRA’s Covid-19 BIMERVAX® vaccine, recently approved by the European Medicines Agency. Virnext has been committed for several years in the development of in vitro and in vivo preclinical models of infections dedicated to the screening and evaluation of antiviral, antibody and vaccine candidates against emergent and re-emergent respiratory viruses...